Erasmus MC
Erasmus MC is the largest university medical center in the Netherlands, operating from Rotterdam as a public academic hospital and research hub with four specialized institutes, a secondary radiotherapy site in Dordrecht, and 10,000+ staff serving patients, trainees, and international research collaborators.
- Company typePrivate
- Founded2002
- HeadquartersRotterdam, Netherlands
- Headcount5,001–10,000
- GTM typeB2C
- OfferingServices
What Erasmus MC does
Erasmus MC is the largest and most versatile of the eight university medical centers (umcs) in the Netherlands, headquartered in Rotterdam and affiliated with Erasmus University Rotterdam. It operates as a public academic medical institution delivering specialized tertiary healthcare, biomedical research, and medical education from undergraduate through postdoctoral levels, with approximately 10,000 employees across a main Rotterdam campus and a secondary radiotherapy location in Dordrecht. Patient care is organized around four specialized sub-brands: Sophia Children's Hospital (Sophia Kinderziekenhuis), the Cancer Institute (Kanker Instituut), the Transplant Institute (Transplantatie Instituut), and the Heart & Vascular Institute (Hart en Vaat Instituut), supplemented by a full range of specialty clinics accessed through physician referral, emergency services, and self-referral for select outpatient services.
Core clinical capabilities include advanced radiotherapy (12 linear accelerators, CyberKnife robotic radiosurgery, brachytherapy, hyperthermia, plus proton therapy through the Holland PTC joint venture), diagnostic radiology and nuclear medicine (PET-CT, PET-MRI, MRI, CT, mammography, interventional radiology), pediatric care, organ transplantation, and cardiovascular interventions. Patient-facing digital services include the "Mijn Erasmus MC" portal and the Digizorg mobile application, and the institution runs the MBB bachelor's program in Medical Imaging and Radiation Therapy in collaboration with Hogeschool Inholland.
Revenue is generated through Dutch healthcare insurance reimbursements and government healthcare allocations for service delivery, supplemented by competitive research grants (notably EU Horizon 2020, IHI, and ERC Advanced Grants) and industry partnerships. Recent grant cadence includes a €38.4M five-year SEISMIC consortium led with Royal Philips and €23.5M IHI plus €14.9M in-kind contributions. The go-to-market combines direct tertiary referrals from regional hospitals and GPs with a research commercialization arm via NeOncoFRAx (personalized cancer vaccines). Customer segments span patients requiring specialized complex care, medical trainees and healthcare professionals, and academic/research institutions conducting translational research collaborations.
Erasmus MC firmographics
Firmographics- Name
- Erasmus MC
- Legal name
- Erasmus MC
- Website
- https://erasmusmc.nl
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Erasmus MC is the largest university medical center in the Netherlands, operating from Rotterdam as a public academic hospital and research hub with four specialized institutes, a secondary radiotherapy site in Dordrecht, and 10,000+ staff serving patients, trainees, and international research collaborators.
- Ownership category
- akta.pro rank
Erasmus MC industry classification
Industry- Product category
- Academic Medical Center / Tertiary Healthcare Services
- NAICS
- General Medical and Surgical Hospitals (62211), Medical Laboratories (621511), Diagnostic Imaging Centers (621512)
- SIC
- Services-General Medical & Surgical Hospitals, Nec (8062)
- akta.pro primary industry
- Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)
- akta.pro secondary industries
- Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM), Central Laboratory Services (Core Lab Operations) (HLAGAEAA)
Keywords
Where Erasmus MC is headquartered
LocationHeadquarters
- HQ city
- Rotterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices2 records
Markets served
Erasmus MC business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Others
Revenue model
- Healthcare Service Delivery: Direct patient care services including consultations, diagnostics, treatments, surgeries, and hospital stays. Revenue generated through healthcare insurance claims and government healthcare funding schemes.
- Research Grants and Funding: EU Horizon 2020 funding (VEO project EUR 23.5M), IHI funding for SEISMIC consortium (EUR 23.5M plus EUR 14.9M in-kind contributions), ERC Advanced Grants for researchers, and various clinical research collaborations
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Erasmus MC product offering
Product offeringCore offering
Erasmus MC is the largest university medical center in the Netherlands, providing specialized tertiary healthcare through four institutes (Cancer Institute, Transplant Institute, Heart & Vascular Institute, and Sophia Children's Hospital). It combines patient care with biomedical research and medical education, supported by advanced radiotherapy, imaging, and surgical capabilities. The institution also runs major European research consortia and operates a subsidiary (NeOncoFRAx) developing personalized cancer vaccines.
Product overview
Erasmus MC is a comprehensive university medical center in Rotterdam, Netherlands, operating as a single unified healthcare institution with four specialized sub-brands: Sophia Children's Hospital (pediatric care), Cancer Institute (oncology services), Transplant Institute (organ transplantation), and Heart and Vascular Institute (cardiovascular care). The center provides a full range of medical services including radiotherapy with advanced technologies (linear accelerators, CyberKnife, proton therapy via Holland PTC partnership), radiology and nuclear medicine diagnostics, organ perfusion, and digital patient services (Mijn Erasmus MC portal and Digizorg app). Education and research are integral to the mission, with numerous medical training programs and clinical research initiatives. The institution also operates NeOncoFRAx, a subsidiary developing personalized cancer vaccines.
Differentiator
Problem solved
Functional benefit
Brands
- Sophia Kinderziekenhuis (Sophia Children's Hospital): Specialized children's hospital within Erasmus MC providing healthcare for children
- Erasmus MC Kanker Instituut (Cancer Institute)
- Erasmus MC Transplantatie Instituut (Transplant Institute)
- Erasmus MC Hart en Vaat Instituut (Heart and Vascular Institute)
- NeOncoFRAx
Products and services
- Sophia Kinderziekenhuis (Sophia Children's Hospital)
- Erasmus MC Kanker Instituut (Cancer Institute)
- Erasmus MC Transplantatie Instituut (Transplant Institute)
- Erasmus MC Hart en Vaat Instituut (Heart and Vascular Institute)
- Radiotherapie (Radiotherapy)
- Protonentherapie (Proton Therapy)
- Radiologie & Nucleaire Geneeskunde (Radiology & Nuclear Medicine)
- Mijn Erasmus MC (Patient Portal)
- Digizorg App
- MBB Opleiding (Medical Imaging and Radiation Therapy Program)
- NeOncoFRAx Personalized Cancer Vaccine
Quantifiable outcome
- Treats 5,100+ radiotherapy patients annually across two locations
- +3 more outcomes
Companies that use Erasmus MC
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Erasmus MC technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Erasmus MC partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and flagship.
- AIIMS BhopalcoreResearch collaboration in pharmacogenomics to advance individualized prescription practices. A delegation from Erasmus MC visited AIIMS Bhopal and presented a letter of intent to strengthen academic cooperation, with proposed project valued at over Rs 10 crores focused on personalized treatment through genetic testing.
- SkylineDxcoreInternational research collaboration on cutaneous squamous cell carcinoma (CSCC) - largest omics characterization to date involving RNA-sequencing of 366 tumors and whole-exome sequencing of 147 tumors. SkylineDx introduced SCCore GEP, a novel gene expression signature for metastatic risk stratification.
- University of California, San FranciscocoreInternational research collaboration alongside SkylineDx and Erasmus MC for cutaneous squamous cell carcinoma omics characterization study presented at 83rd Society for Investigative Dermatology Annual Meeting.
- Thermo Fisher Scientific (PPD)coreAgreement for Phase 3 clinical trial design for Ampligen in late-stage pancreatic cancer. PPD clinical research business assisting with trial planning and regulatory requirements.
- AstraZenecacoreOngoing collaboration on Phase 2 DURIPANC study for pancreatic cancer treatment with Ampligen, expected to complete enrollment later in 2026.
- Royal PhilipsflagshipAcademic lead in SEISMIC research consortium coordinated by Philips, receiving EUR 23.5M IHI funding for 5-year neurosurgery research program with 8 clinical studies targeting minimally invasive brain treatments. Consortium includes 9 industry partners, 2 patient organizations, and 7 academic partners.
- NeOncoFRAxcoreSubsidiary of Erasmus MC developing personalized cancer vaccines for pancreatic cancer and solid tumors. Therapy currently in clinical research with promising results in prolonging patients' lives, focused on affordability and accessibility.
- VEO Consortium (Horizon 2020)coreVersatile Emerging Infectious Disease Observatory - four-year EU Horizon 2020-funded research initiative (2020-2024) coordinated by Erasmus MC, involving 19 European partner institutions across 12 countries for early warning and monitoring of emerging infectious diseases.
- Holland PTCcoreProton therapy treatment center established jointly with LUMC and TU Delft. Erasmus MC refers patients requiring proton therapy to Holland PTC while providing conventional radiotherapy at its own facilities in Rotterdam and Dordrecht.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Erasmus MC competitors and assessment
Company assessmentBroad incumbents
- Mayo Clinic: Large US-based non-profit academic medical center with integrated clinical care, research, and education across multiple specialties. Comparable in mission and structure though much larger and more globally commercialized.
Direct peers
- Amsterdam UMC: University medical center formed by the merger of AMC and VUmc in the Netherlands. Most direct peer to Erasmus MC as a fellow large Dutch UMC providing tertiary care, research, and education.
- UMC Utrecht: Major Dutch university medical center with comparable structure in patient care, biomedical research, and education, including specialized oncology and pediatric services.
- University Medical Center Groningen (UMCG): Dutch university medical center providing tertiary care, biomedical research, and medical education; comparable in scale and academic mission to Erasmus MC.
- Karolinska University Hospital: Swedish academic medical center affiliated with Karolinska Institute, delivering tertiary care, biomedical research, and education. Comparable scale and mission to Erasmus MC as a leading European academic medical center.
- King's College Hospital (King's Health Partners): Major UK academic medical center delivering tertiary and quaternary care, with a strong research portfolio and academic affiliation. Comparable as a European academic hospital system.
- Charité – Universitätsmedizin Berlin: One of Europe's largest university medical centers, combining clinical care, research, and teaching across multiple campuses. Directly comparable to Erasmus MC in mission and European academic standing.
- Leiden University Medical Center (LUMC): Dutch university medical center that is a direct peer in tertiary care, research, and education; also a partner in the Holland PTC proton therapy venture with Erasmus MC.
- Radboud University Medical Center (Radboudumc): Dutch university medical center delivering tertiary care, research, and education with similarly broad specialty coverage and academic medical center structure.
Emerging players
- MD Anderson Cancer Center: Specialized academic cancer center with extensive translational research and clinical trials, including pancreatic cancer work. Comparable to Erasmus MC's Cancer Institute as a peer for oncology specialization and trial leadership.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Erasmus MC social profiles
Digital presenceErasmus MC financial estimates
Financial estimateRevenue estimate
Valuation estimate
Erasmus MC leadership team
Management profileNumber of profiles
Profiles2 records
Erasmus MC subsidiaries and ownership
Company hierarchySubsidiaries1 record
Erasmus MC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Erasmus MC M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Erasmus MC
What does Erasmus MC do?
Erasmus MC is the largest university medical center in the Netherlands, providing specialized tertiary healthcare through four institutes (Cancer Institute, Transplant Institute, Heart & Vascular Institute, and Sophia Children's Hospital). It combines patient care with biomedical research and medical education, supported by advanced radiotherapy, imaging, and surgical capabilities. The institution also runs major European research consortia and operates a subsidiary (NeOncoFRAx) developing personalized cancer vaccines.
Is Erasmus MC a public or private company?
Erasmus MC is a private company. It is classified as corporate owned and is currently operating.
When was Erasmus MC founded?
Erasmus MC was founded in 2002. It employs 5,001 to 10,000 people.
Where is Erasmus MC based?
Erasmus MC is headquartered in Rotterdam, Netherlands, in the Europe region.
How does Erasmus MC make money?
Two revenue lines are on record. Healthcare Service Delivery is the primary driver. The others are research Grants and Funding.
Who are Erasmus MC's main competitors?
Mayo Clinic is listed as a broad incumbent. Direct peers are Amsterdam UMC, UMC Utrecht, University Medical Center Groningen (UMCG), Karolinska University Hospital, King's College Hospital (King's Health Partners), Charité – Universitätsmedizin Berlin, Leiden University Medical Center (LUMC) and Radboud University Medical Center (Radboudumc). MD Anderson Cancer Center is listed as an emerging player.
Does Erasmus MC have an API?
No public API is recorded for Erasmus MC.
What industry is Erasmus MC in?
Erasmus MC's product category is Academic Medical Center / Tertiary Healthcare Services. Its primary akta.pro industry code is EDAHAGAA, Academic Medical Centers & Teaching Hospitals (University-Affiliated), with a secondary code of EDAHAGAI, Biomedical Sciences & Medical Research Institutes (University-Based). Its NAICS code is 62211 and its SIC code is 8062.